Anti-QSOX1 Antibody for Treating Cancer and Metastasis

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Cancer, and especially cancer metastasis, is a leading cause of death worldwide. Research in recent years highlighted the importance of the extracellular matrix (ECM) surrounding the tumor in cancer progression metastasis formation. Therefore, many attempts currently address the unmet need to target enzymes that remodel the ECM to treat cancer. The current technology is a monoclonal antibody that specifically inhibits QSOX1, an enzyme that remodels the ECM and is up-regulated in several cancers. The antibody effectively inhibited tumor progression and metastasis formation in several mouse models, especially when combined with chemotherapies.
The antibody potentially offers a generalized treatment for several cancer types as a single agent or in combination with standard of care chemotherapies.


Background and Unmet Need

Cancer is a leading cause of death worldwide, accounting for almost 10 million deaths in 2020. The primary cause of death from cancer is metastasis,1 demonstrating that despite the ongoing developments in cancer research, there is still an unmet need for therapeutic agents with significant efficacy against solid tumors and metastases formation. The significant role of the tumor microenvironment in tumor development has become evident in the past few years. The ECM is a substantial component of the niche surrounding cells and affects tumorigenesis and metastasis. Therefore there is a need for ECM modulating agents for treating cancer. Laminin is an important protein of the ECM, as it plays a central role in cell adhesion and migration. Interestingly, laminin is up-regulated in invasive breast carcinomas and was shown to contribute to tumor progression.

Consequently, drugs that target ECM composition by inhibiting laminin incorporation hold great potential as a broadspectrum treatment for various cancers and metastasis. QSOX1 is an enzyme that is essential for the incorporation of the protein scaffold laminin into the ECM. Cells lacking the QSOX1 enzyme show reduced cell adherence and perturbed migration.

The Solution

The group of Prof. Deborah Fass developed a monoclonal antibody (mAb) that specifically inhibits extracellular

QSOX1 enzyme’s activity.

Technology Essence
Quiescin sulfhydryl oxidase (QSOX) catalyzes the insertion of disulfide bonds into unfolded, reduced proteins.
QSOX1 expression is up-regulated in the stroma of aggressive breast carcinomas and in a variety of adenocarcinomas, including breast, lung, pancreas, and prostate.2 The group of Prof. Deborah Fass previously demonstrated that knockdown of QSOX1 reduced ECM laminin content, resulting in decreased cell adhesion and reduced cell migration of cancer cells.3 The group further developed a monoclonal antibody (mAb) that specifically inhibits QSOX1 activity by sterically blocking the enzyme's active site. They showed that the antibody affected the ECM produced by cancer-associated stromal fibroblasts, resulting in decreased tumor growth and metastasis in murine cancer models. Importantly, the antibody had an added benefit when provided together with chemotherapy (Figure 1)2.
Figure 1. Syngeneic triple-negative breast cancer (TNBC) model treated with QSOX1 inhibitory monoclonal antibody and chemotherapy. (A) Mice bearing 4T1 tumors were treated with control IgG, MAb316.1 alone (30mg/kg), doxorubicin (8 mg/kg), or a combination of doxorubicin and MAb316.1. Reported tumor volumes were measured externally on the indicated days and averaged for each treatment group. (B) Number of lung metastases in treatment groups from two experiments with the 4T1 model. (*

Applications and Advantages

  • Therapeutic agent for treating various cancers and inhibiting metastasis
  • Can possibly be combined with existing treatments for an enhanced effect
  • A possible use for treating laminin-associated diseases
  • The mAb only targets the extracellular fraction of QSOX1 without affecting its intracellular activities, which have important physiological roles (in contrast to a small molecule inhibitor).

Development Status

Prof. Fass and her team have characterized the effect of QSOX1 inhibition on the adhesion and migration of cells. They developed an antibody specifically for QSOX1 (with cross-reactivity to human and mouse QSOX1), demonstrated its effectiveness in QSOX1 inhibition, and showed it decreases tumor growth and metastasis in murine cancer models (syngeneic breast cancer model, syngeneic melanoma model, and xenograft model of human breast cancer). In addition, the group has developed a partially humanized version of the mAb, and is actively working on the development of a fully human version.


Feldman T, Grossman-Haham I, Elkis Y, et al. Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models. Oncotarget. 2020;11(4):386-398. doi:10.18632/oncotarget.27438 [1] Ilani T, Alon A, Grossman I, et al. A Secreted Disulfide Catalyst Controls Extracellular Matrix Composition and Function. Science. 2013;341(6141):74-76. [2]

Intellectual property status

  • Granted Patent
  • Patent application number :USA Granted: 10,829,561 USA Granted: 9,631,028 USA Published: Publication Number: 2021-0292437-A1

Related Keywords

  • Biological Sciences
  • Medical Research
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Medical Health related
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support